Selected article for: "aerosol transmission and SARS spread"

Author: Wu, Ting; Kang, Shuntong; Peng, Wenyao; Zuo, Chenzhe; Zhu, Yuhao; Pan, Liangyu; Fu, Keyun; You, Yaxian; Yang, Xinyuan; Luo, Xuan; Jiang, Liping; Deng, Meichun
Title: Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19)
  • Cord-id: 8eg3sbtv
  • Document date: 2021_7_6
  • ID: 8eg3sbtv
    Snippet: The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to public concern worldwide. Although a variety of hypotheses about the hosts of SARS-CoV-2 have been proposed, an exact conclusion has not yet been reached. Initial clinical manifestations associated with COVID-19 are similar to those of other acute respiratory infections, leading to misdiagnoses and resulting in the outbreak at the early stage. SARS-CoV-
    Document: The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to public concern worldwide. Although a variety of hypotheses about the hosts of SARS-CoV-2 have been proposed, an exact conclusion has not yet been reached. Initial clinical manifestations associated with COVID-19 are similar to those of other acute respiratory infections, leading to misdiagnoses and resulting in the outbreak at the early stage. SARS-CoV-2 is predominantly spread by droplet transmission and close contact; the possibilities of fecal–oral, vertical, and aerosol transmission have not yet been fully confirmed or rejected. Besides, COVID-19 cases have been reported within communities, households, and nosocomial settings through contact with confirmed COVID-19 patients or asymptomatic individuals. Environmental contamination is also a major driver for the COVID-19 pandemic. Considering the absence of specific treatment for COVID-19, it is urgent to decrease the risk of transmission and take preventive measures to control the spread of the virus. In this review, we summarize the latest available data on the potential hosts, entry receptors, clinical features, and risk factors of COVID-19 and transmission routes of SARS-CoV-2, and we present the data about development of vaccines.

    Search related documents:
    Co phrase search for related documents
    • acute kidney injury and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute kidney injury and liver enzyme: 1, 2, 3
    • acute kidney injury and local inflammation: 1, 2, 3
    • acute kidney injury and long duration: 1
    • acute kidney injury and long virus: 1
    • acute kidney injury and low infection rate: 1
    • acute kidney injury and lung tissue: 1, 2, 3, 4, 5, 6, 7
    • acute kidney injury and lymph node: 1, 2
    • acute kidney injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • additional study and admission time: 1, 2, 3
    • additional study and liver lymphocyte: 1
    • additional study and low infectiousness: 1
    • additional study and lymphocyte count: 1, 2, 3
    • admission time and liver enzyme: 1, 2, 3
    • long duration and low transmission: 1
    • long duration and lung lesion: 1
    • lung tissue and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • lung tissue and lymphocyte count: 1, 2
    • lung tissue and lysosome endosome: 1